HLA HLA HLA-QC QCWS 11 DNA-QC 15 DNA-QC 16 DNA SSP 18 DNA SSO LABType 19 DNA SSO WAKFlow GenoSearch

Size: px
Start display at page:

Download "HLA HLA HLA-QC QCWS 11 DNA-QC 15 DNA-QC 16 DNA SSP 18 DNA SSO LABType 19 DNA SSO WAKFlow GenoSearch"

Transcription

1 HLA HLA HLA-QC QCWS 11 DNA-QC 15 DNA-QC 16 DNA SSP 18 DNA SSO LABType 19 DNA SSO WAKFlow GenoSearch 21 DNA SBT 23 QC 25 QC 26 FCM FlowPRA 28 WAKFlow 29 LABScreen 31 LIFECODES MHC Instructions to Authors (updated on Feb. 19, 2019) Major Histocompatibility Complex Official Journal of Japanese Society for Histocompatibility and Immunogenetics JSHI

2 Major Histocompatibility Complex 2019; 26 (1): Frans Claas Immunohematology and Blood Transfusion, Leiden University Medical Center Transplantation of highly sensitized patients & HLA epitope matching to prevent sensitization Eric Spierings Laboratory of Translational Immunology, University Medical Center Utrecht T-cell epitopes in HLA-mismatched transplantations HLA B cell EPITOPE Frans Claas T cell EPITOPE Eric Spierings B cell EPITOPE T cell EPITOPE de novo DSA HLA DNA

3 MHC 2019; 26 (1) 28 2 TEL: QCWS HLA TEL:

4 Major Histocompatibility Complex 2019; 26 (1): MHC Web

5 MHC 2019; 26 (1) FAX MHC

6 Major Histocompatibility Complex 2019; 26 (1): HLA TEL HLA HLA 2 HLA HLA HLA 3 HLA 5

7 Major Histocompatibility Complex 2019; 26 (1): 6 QC HLA HLA 1 HLA :30 20: WS1 HLA WS2-1 WS2-2 5 WS1 WS WS

8 Major Histocompatibility Complex 2019; 26 (1): HLA % 93 77% 3 2% % % 14 12% 11 9% % 6 5% % 77 59% % 2 2% 10 8% 1 1% 9 7% 3 2% % 61 50% 9 7% 3 2% % 14 19% 7

9 MHC 2019; 26 (1) 平成 30 年度 認定 HLA 検査技術者講習会アンケート集計結果 4 学会ホームページに掲載された 講習会テキストの事前確認の有無 あり 94 名 78% なし 27 名 22% 5 講習科目の種類は適切であったか 6 講習内容のレベルならびに講習テキストは適切であったか 7 講習時間は量的に適切であったか 8 回答者 121 名

10 30 HLA MHC 2019; 26 (1) 8 9 PDF HP HP QCWS HLA HLA HLA-G MHC NK MHC H25 27 H30 9

11 Major Histocompatibility Complex 2019; 26 (1): QC HLA WG HLA WG WG WG WG 10

12 Major Histocompatibility Complex 2019; 26 (1): HLA-QC 22 HLA-QC QCWS 1) 1) QCWS # HLA-QCWS 81 1 DNA-QC 74 QC DNA-QC QC 26 QCWS 4 9 QCWS HLA QC CD-R 111 MHC 2 QCWS DNA-QC DNA DNA HLA 3 DNA HLA # QCWS 1) 2) 3) 4) 5) 6) 7) 8) 9) 10) 11) 12) 8) 13) 14) 13) 15) 16) 1) 2) 3) 4) 5) 6) 7) 8) 9) 10) HLA 11) 12) 13) HLA 14) 15) 16) 11

13 MHC 2019; 26 (1) 第 22 回 HLA-QC ワークショップレポート 表1 第 22 回 HLA-QCWS 参加施設 胞を選定した 4 種類の購入細胞を培養した後 抽出し ②抗体と DNA の結果から正しく適合判定が行えるこ た DNA を約 100 ng/μl の濃度で 100 μl SSP 実施施設 とをテーマとして 指定した抗体試料と DNA 試料の測 は倍量 ずつ配布した これとは別に SSO ルミネッ 定結果による HLA クラス I とクラス II を対象とした仮 クス法の陰性コントロール DNase free water 50 μl を 想クロスマッチ 配布し 各施設で陰性コントロール データの取得を必 また 日本移植学会連携クロスマッチでは 抗体 QC 須とした で使用する試料を一部共用して実施した 抗体 QC のテーマは ①抗体検査が適正な操作過程に 3 解析報告と担当者 基づき正確に行えること ②エピトープと許容抗原によ り正確な抗体特異性解析が行えること ③検査結果から 解析は 主に前年度と同一担当者に それぞれの担当 導かれる総合判定結果を正しく報告できることの 3 点と 項目を入れ替えて依頼した 解析結果の公表は QCWS した 抗体試料は 本学会から提供依頼した日本赤十字 集会での報告 学会公式サイトへの掲載 データ集 CD-R の配布 学会誌への掲載の 4 通りとした 社に保管してある献血者由来の抗血清 4 種類を選定し た これらは 過去の QCWS で使用歴があり 当時の 集会では タイピング結果解析 DNA-QC と抗体検 解析結果に課題を見出した抗血清とした 血清化処理し 査結果解析 抗体 QC に分け それぞれ試料説明 検 た後 各施設に 1 ml ずつ配布した 査方法別解析 総合解析の順に報告した DNA-QC では クロスマッチについては 本年も参加希望施設からの 新表記法の問題点とその解説 評価点と操作工程の関係 募集参加として以下の 2 通りで実施することを提示し ソフトウェアの活用 ビーズカウントの問題 コンタミ それぞれ参加申込み時に受け付けた ネーションの状況などが報告された 抗体 QC では 総 ①配布検体の一部を使用しクロスマッチを正確に行え 合判定結果不一致であった要因 スクリーニング検査の ることをテーマとして 指定した抗体試料と各施設で準 位置づけ コントロールの重要性 バックグラウンド処 備した細胞で HLA クラス I を対象としたダイレクトク 理などが報告された 最後に総合討論として 公開バー ロスマッチ チャルクロスマッチ を企画し 各臨床部門の参加者を 12

14 22 HLA-QC MHC 2019; 26 (1) 1 DNA SSP SSO SSO SBT Sanger NGS 2 FCM FlowPRA # # # SSO LABType WAKFlow/ Genosearch # LABScreen WAKFlow LIFECODES 4 QCWS DNA DNA Ambiguity 1 DNA HLA-A, B, C, DRB1, DQB1, DPB1 IMGT/HLA HLA HLA-QC DNA 13

15 MHC 2019; 26 (1) 第 22 回 HLA-QC ワークショップレポート 表3 第 22 回 HLA-QC ワークショップレポート 抗体サンプルの総合結果 した 表 2 の 2 に達しない抗原として表示した HLA 遺伝子頻度 抗体試料は 参加各施設の総合判定結果を集計し は本学会 HLA 標準化委員会が公開している HLA 推定 HLA 遺伝子頻度 0.1% 以上の抗原に対する特異性につい アレル一覧表 JSHI 2018 年度版 を参照した 表 3 て記載した スコア 8 は 3 分の 2 以上の参加施設が これらの結果を各施設の結果の再確認 精度管理及び 陽性判定した抗原 スコア 1 は 3 分の 2 以上の参加 技術向上に活用していただきたい 施設が陰性判定した抗原 スコア 4 はどちらも 3 分 14

16 22 HLA-QC 22 HLA-QC DNA-QC 1) 1) 1 DNA-QC HLA-A, B, C, DRB1 QCWS 2 22ndDNA-QC 3 H3003 H3004 B44 A*33:03- C*14:03-B*44:03-DRB1*13:02 2 A*03:01-C*05:01-B*44:02-DRB1*13:01 48 HLA 1 HLA HLA 3 DNA 100 ng/μl 4 DNase free water SSO 21stQCWS 15

17 22 HLA-QC 22 HLA-QC DNA-QC 1) 1) 1 DNA-QC % % % 6 8.1% HLA-A B C DRB1 DRB3/4/5 DQB1 DPB1 DQA1 DPA1 SSO Luminex 74.3% QCWS HLA 2017 ambiguity HLA DNA A B C 3 B 11 C 1 BC 13 Luminex SSO 11 3 ambiguity H3003 DPA1*02:08 SSO ambiguity DPA1*02:01 DPA1*02:01 ambiguity HLA B SSO 16

18 22 HLA-QC MHC 2019; 26 (1) 17

19 22 HLA-QC 22 HLA-QC DNA SSP 1) 1) HLA Fusion SSP 2 false positive 1 5 SSP

20 22 HLA-QC 22 HLA-QC DNA SSO LABType 1) 1) 1 LABType % HLA-A HLA-B HLA-C HLA-DRB1 LABType SSO LABType HD LABType XR LABType HD HLA-A HLA-B HLA-C HLA-DRB1 LAB- Type XR HLA-C 2 LABType SSO HLA-A HLA-B HLA-C HLA-DRB1 1 HLA-DQ HLA-DP 4 HLA-DRB H3001 H Pmin/Nmax 22 QC LABType SSO HLA-B H3001 H3004 PCR LABType SSO HLA-DQ H3001 H3004 PCR LABType SSO HLA-C 1 19

21 MHC 2019; 26 (1) 4 22 HLA-QC 1 20

22 22 HLA-QC 22 HLA-QC DNA SSO WAKFlow, GenoSearch 1) 1) SSO Luminex % WAKFlow 41 3 GenoSearch 5 1 WAKFlow GenoSearch SSO SBT WAKFlow 5 GenoSearch 2 WAKFlow GenoSearch WAKFlow 41 HLA-A HLA-B HLA-DRB1 38 HLA-C 36 HLA-DQB1 23 HLA-DPB HLA-DQA1 GenoSearch 5 HLA-A -B -C -DRB P/N 5 D#37TG WAKFlow HLA- DRB1 22 QC PCR 3 4 P/N P/N 21

23 MHC 2019; 26 (1) 5 WAKFlow HLA-DRB1 D#37TG 4 22 HLA-QC WAKFlow SSO Luminex Genosearch 22

24 22 HLA-QC 22 HLA-QC DNA SBT 1) 1) 1 Sanger 4 3 Secore 1 AlleleSEQR Secore 3 utype7.1 AlleleSEQR 1 Assign-SBT v4.7 Secore Class II 3 DRB1 DQB1 exon 2, 3 DPB1 exon 2, 3, 4 Class I A B exon 2, 3, 4 2 exon 1, 2, 3, 4, 5 1 C exon 2, 3, 4 2 exon 1, 2, 3, 4, 5, 6, 7 1 AlleleSEQR Class I exon 2, 3, 4 DRB1 DPB1 exon 2 DQB1 exon 2, 3 NGS 3 2 All- Type NGS 1 ScisGo HLA AllType NGS 2 TypeStreamVisual 1 NGS engine ScisGo HLA Gems-HLA AllType NGS 2 A B C DQA1 DPA1 Full gene exon intron DRB1/3/4/5 DQB1 DPB1 exon 2 3 UTR ScisGo HLA DPA1 exon 2, 3, 4 A B C DRB1/3/4/5 DQB1 DPB1 DQA1 exon 2 1 Sanger Sanger 2 NGS NGS 2 Quality Value Quality Scores Sanger Sanger 4 Q20 Quality Value NGS NGS 3 Q20 Q20 3 Noise/Signal Sanger Sanger 4 Noise/Signal 8% 23

25 MHC 2019; 26 (1) 4 NGS % All- Type NGS 2 H3001 DQB1 Consensus Consensus 22 HLA-QC 3 Sanger NGS Sanger Quality Value NGS 24

26 22 HLA-QC 22 HLA-QC QC 1) 1) HLA-C IgM HLA QCWS QCWS High Background SH3001 SH3002 DQ SH3003 HLA SH3004 SH3002 SH3004 QC SH3003 II DQ CD 25

27 22 HLA-QC 22 HLA-QC QC 1) 1) 1 1 QC QCWS % % % HLA SH3002 SH3004 I II 97% SH3001 I 87% II 40% HLA LABScreen single antigen 41 WAKFlow HLA HR 21 LIFECODES 4 Luminex 2 HLA 2 1 HLA 0.1% HLA 0.67 SH A 47 A % B C 1 2.1% 2 90% I 43 II 23 I SH % 26

28 22 HLA-QC MHC 2019; 26 (1) II SH % LABScreen single antigen Lot MFI Score Calmed I II 1 DQ 3 QC 27

29 22 HLA-QC 22 HLA-QC FCM FlowPRA 1) 1) 1 Screening Class I 22 Class II 21 3 Single Antigen 2 3 %PRA Negative Control %PRA 3 SH3001 SH % LOT 5 FCM Luminex %PRA QCWS 28

30 22 HLA-QC 22 HLA-QC WAKFlow 1) 1) 1 QC 61 WAKFlow % MR Class I 15 MR Class II 8 HR Class I II 21 HR LABScreen Single Antigen LS-SA 6 HR WAKFlow MR Class I Class II BB PB BB SH3002 PB Median Median Index Median 2SD Index Lot Index SH3001 SH3002 SH3001 Class I 12/15 80% Class II 2/8 25% SH3002 Class II 6/8 75% 8 2 WAKFlow HR Class I Class II BB PB BB SH3002 PB SH Median Calmed Class I 2 Lot Class II 3 Lot V0A S27 Median Calmed 2SD SH3002 A24 Median Calmed Calmed 1,000 Calmed 1,000 1,000 HR LA-SA Average Calmed 1,000 LS-SA nmfi 1,000 Calmed 5,000 LS-SA Median Calmed 29

31 MHC 2019; 26 (1) 4 QCWS BB Median 500 MR HR Lot Lot Median 2SD Index Calmed MR 8 22 HLA-QC MR MR 1 HR Calmed Median 17 HR LS-SA LS-SA HR HR 30

32 22 HLA-QC 22 HLA-QC LABScreen 1) 1) 1 1 LABScreen Mixed 15 Multi 1 PRA 9 Single Antigen EDTA EDTA QCWS 2 Negative Control Serum Negative Control Serum 5 HLA Fusion NBG Ratio Normalized MFI Negative Control Serum 5 default background values OLINS Negative Control Serum OLINS Negative Control Serum OLINS OLINS QCWS Negative Control Serum 3 Negative Positive Control QC Negative Positive Control Bead Negative Positive Control Bead QCWS 4 SH3001 LABScreen Single Antigen Class II DRB1*04:04 16:02 Lot 3 LABScreen Single Antigen Normalized MFI Negative Control Serum Negative Positive Control Bead 31

33 MHC 2019; 26 (1) 4 HLA Fusion4.2 epitope HLA Fusion4.2 HLA Matchmaker HLA Fusion epitope HLA 22 HLA-QC epitope registry 22 QC 32

34 22 HLA-QC 22 HLA-QC LIFECODES 1) 1) 1) 1 4 LIFECODES LSA Single Antigen LSA 1 LSA HLA LSA HP 22 QCWS 2 4 LSA μl LSA 40 μl 2 20 μl LSA 40 μl 4 NC PC LRA MFI Raw Value LS-SA 3 1 NC PC LRA NC LRA SH3002 PC 2 MFI Class I Class II MFI I 10 μl 2 20 μl Class 1 SH3003 Class II SH3003, SH MFI MFI LS-SA LS-SA nmfi 1,000 nmfi 1,000 3,000 SH LRA SH3002 MFI/ LRA LS-SA 4 MFI 2 20 μl 1 10 μl MFI 1 2 FDA 2 2 LSA 33

35 MHC 2019; 26 (1) SH3002 NC LRA 22 HLA-QC LRA LRA 34

36 22 HLA-QC 22 HLA-QC 1)2) 1) 2) 1 FlowPRA, LABScreen, WAKFlow, LIFECODES HLA SH3001 SH LCT 0 AHG-LCT 1 MPHA 3 FCM 0 ICFA 1 LCT, FCM, ICFA SH3002/HLA Class I LCT 4 AHGLCT 0 FCM 7 ICFA 13 Class I 2 Class I+Class II LCT AHG-LCT MPHA FCM FCS ICFA Class I-1 Class I-2 LCT AHG-LCT SH3002 A24 MPHA SH3002 A2 HLA FCM 10,000 ICFA SH3004 A24 1 index LABSceen Single Antigen LS-SA SH3001 LS-SA B*44:02 nmfi 9,944 B*44:02 LS-SA nmfi 35

37 MHC 2019; 26 (1) 2 SH3003 DNA H3003 DNA 27 DNA HLA LS-SA nmfi WAKFlow HR WAK-HR Calmed A*24:02 nmfi 8,551 Calmed 1,915 B*44:03 nmfi 8,108 Calmed 3,376 B*51:02 nmfi 17,679 Calmed 14,970 DRB1*13:02 nmfi 2,648 Calmed 885 DQB1*03:03 nmfi 17,240 Calmed 5, HLA-QC DQA1*03:02 DQB1*03:03 HLA Class II DRB1 DQB1 11 DR9 DRB1*09:01 DQ3 DQ9 DQB1*03:03 LS-SA DQ3 nmfi 10,000 DQB1 DR9 DQ3 DQB DQ DQA1*03:02 DQA1 5 DQA1*03:02 DQA1*03:

38 22 HLA-QC 22 HLA-QC 1)2) 1) 2) 1 6 QCWS ACD-A 7.5 ml 9 21 QCWS HLA SH SH3004 A*24:02 nmfi=14,102 DRB1*09:01 nmfi=19,073 DRB1*12:01 nmfi=17,430 Donor Specific Antibody; DSA FCXM 7 CDC ICFA 4 CDC+FCXM 14 FCXM 10 FCXM+ICFA % CDC-B 75% FCXM ICFA 2 ICFA 5 FCXM 37

39 Major Histocompatibility Complex 2019; 26 (1): 抄録集 TEL TEL

40 17 MHC 2019; 26 (1) 参加費 1 2, , ,000 会議等 会場地図 TEL JR 350 m 39

41 MHC 2019; 26 (1) 17 プログラム HLA 開会の挨拶 オープニングセミナー 44 HLA 一般演題 (1) 1 HLA 1) 2) 1) 1) 1) 1) 1) 2) 2 LABScreen Single Antigen Beads HLA FCM 1) 1) 1) 1) 1)2) 1) 1) 2) 3 HLA Molecular Mismatch Method HLA class II de novo DSA dndsa 4 IgG HLA 1) 1) 2) 3) 3) 1) 3) 3) 3) 1) 1) 1) 1) 2) 3) 40

42 17 MHC 2019; 26 (1) 一般演題 (2) 5 HLA 1) 1) 1) 1) 1)2) 1) 1) 2) 6 MEK 1) 1) 2) 1) 1) 1) 1) 3) 4) 1) 1) 2) 3) 4) 7 HLA-F 1) 2) Daniel E Geraghty 3) 1) 1) 2) Fred Hutchinson Cancer Research Center 3) ランチョンセミナー HLA I HLA II 後援 : 株式会社ベリタス 世話人会 総会 特別講演 HLA Killer immunoglobulin-like receptor KIR 41

43 MHC 2019; 26 (1) シンポジウム (1) 1 HLA 2 HLA HLA 1) 2) 3) 3) 4) 1) 2) HLA 3) 4) 3 HLA 休憩 シンポジウム (2) HLA 1 de novo DSA 1) 2) 1) 1) 1) 1) 2) 2 3 de novo DSA 1) 2) 2) 2) 3) 3) 4) 4) 2) 2) 2) 5) 2) 1) 2) 3) 4) 5) 意見交換会

44 17 MHC 2019; 26 (1) オープニングセミナー 44 HLA 43

45 MHC 2019; 26 (1) HLA ASHI, American Society for Histocompatibility and Immunogenetics 1 NGS Next Generation Sequencing 2 FcRn neonatal Fc receptor FcRn IgG IgG MHC I FcRn ph IgG IgA IgM 5 6 IgG FcRn Rozanolixizumab I 3 CAR-T Chimeric antigen receptor T cell CAR-T T T CAR-T CTL 2017 B ALL 2018 DLBCL FDA 4 CRISPR-Cas9 Clustered Regularly Interspaced Short Palindromic Repeats-Cas9 CRISPR-Cas9 DNA CRISPR-Cas9 PAM Hot topics Best poster Rheumatoid Arthritis, RA HLA- DRB1 71 K E DRB1*04:01 K71E RA 5 Non-HLA AMR Non-HLA MICA alloantibody AT1R, ETAR, Vimentin Autoantibody AT1R AMR nm mrna mirna HLA BOS HLA Collagen-V Col-V 6-2 DNA cell free DNA, cfdna 44

46 17 MHC 2019; 26 (1) DNA ng/ml 160 base pair 2 cfdna AMR 7 UNOS mtilda HLA UNOS API developer.unos.org/ 45

47 MHC 2019; 26 (1) 一般演題 (1) 演題番号 1 ~ 4 46

48 17 MHC 2019; 26 (1) 1 HLA 1) 2) 1) 1) 1) 1) 1) 2) HLA Donor Specific Antibody DSA HLA HLA Cw12 Cw14 B40 DR2 Cw11 DR6Y HLA DSA 47

49 MHC 2019; 26 (1) 17 2 LABScreen Single Antigen Beads HLA FCM 1) 1) 1) 1) 1)2) 1) 1) 2) HLA DSA FCM-XM FCM-XM 382 LABScreen Single Antigen Beads DSA Mean Fluorescence Intensity Mean FI T cell B cell FCM-XM MFI 7 Class I B- cell FCM-XM DSA /FCM-XM 7 FCM-XM MFI Pt/ NC >2 Class II HLA B-cell FCM-XM DSA /FCM-XM DSA / FCM-XM 4 3 FCM-XM Pt/NC >2 Class I DSA MFI T cell FCM-XM MFI R 2 = Class II DSA MFI B cell FCM-XM MFI R 2 = Class I HLA DSA T cell FCM-XM DSA /FCM-XM 7 DSA MFI DSA /FCM-XM LABScreen Single Antigen Beads FCM-XM DSA non-hla 48

50 17 MHC 2019; 26 (1) 3 HLA Molecular Mismatch Method HLA class II de novo DSA dndsa % HLAclass II dndsa HLA-DQ HLA dndsa ABMR DSA ABMR HLA HLA HLA Molecular Mismatch Method HLA HLA class II dndsa ABMR 14 non-abmr 12 2 HLA Cambridge HLA Immunogenicity algorithm EMS HMS Duquesnoy s HLA Structural Model Linear Epitope Conformational Epitope HLA C3d Luminex SAB Immucore HLA Epitope Registry HLA dndsa DSA DSA DSA EMS 31.7vs13.7 HMS 31.1vs12.0 DSA DSA EMS HMS DRB1 DRB3/4/5 DQA1/B1 EMS: 55.5vs21.4 HMS: 57.2vs19.5 P=0.0024, P= HLA dndsa C3d ABMR 36 DSA C3d DSA 30 C3d DSA non-abmr 14 DSA C3d DSA C3d(+)DSA C3d( ) DSA EMS HMS 36.9vs vs21.5 C3d(+)DSA C3d( )DSA P=0.0278, P= HLA 1 HLA class II dndsa 2 HLA-DQ HLA class II 3 DSA 49

51 MHC 2019; 26 (1) 17 4 IgG HLA 1) 1) 2) 3) 3) 1) 3) 3) 3) 1) 1) 1) 1) 2) 3) NAIT NAIT HLA HPA HLA U N HLA A26/33 B61/58 U A2/33 B51/58 N A1/26 B37/ HLA LABScreen Single Antigen OneLambda IgG A1 A2 B37 B51 U N U A2 B51 N A1 B37 A2 B51 A1 IgG A2 B51 A1 IgG1 IgG2 A2 B51 IgG1 IgG2 A1 N A2 B51 IgG3 IgG4 A2 B51 A1 IgG1 IgG2 HLA IgG3 NAIT HLA NAIT 50

52 17 MHC 2019; 26 (1) 一般演題 (2) 演題番号 5 ~ 7 51

53 MHC 2019; 26 (1) 17 5 HLA 1) 1) 1) 1) 1)2) 1) 1) 2) HLA HLA 2 HLA-C*01:02,*08:01 SSP HLA-C*01:02,*08:22 WAKFlow SSOP HLA HLA QCWS

54 17 MHC 2019; 26 (1) 6 MEK 1) 1) 2) 1) 1) 1) 1) 3) 4) 1) 1) 2) 3) 4) 1 MEK mitogen-activated protein kinase T PPARγ MEK Streptozotocin H-2b MHC H-2d 28 MEK PCR T in vitro MEK MEK 30 vs ; p<0.01 MEK 7 T MEK Effector CD4+ T cell 44.0% vs. 58.3%; p=0.03 Naïve CD4+ T cell 42.2% vs. 30.5%; p=0.02 MEK IL-2/IFN-γ MEK 24 viability MEK naïve CD4 T Effector T MEK 53

55 MHC 2019; 26 (1) 17 7 HLA-F 1) 2) Daniel E Geraghty 3) 1) 1) 2) Fred Hutchinson Cancer Research Center 3) HLA-F HLA Ib HLA-F killer immunoglobulin like receptor (KIR)-3DL2 NK HLA-F mrna HLA-F KIR HLA-F HLA-F No.1167 HLA-F HLA-F t-test; p= HLA-F HLA-F HLA-F 54

56 17 MHC 2019; 26 (1) ランチョンセミナー HLA I HLA II 55

57 MHC 2019; 26 (1) 17 HLA 1) 2) 1) 2) HLA HLA HLA One Lambda Inc. 2 HLA HLA HLA Non-HLA LABScan Luminex LABScreen Autoantibody HLA CDC FCXM DSA Donor Specific Antibody FlowDSA- XM HLA A B C DR HLA Class II DP DQ HLA DP DQ 56

58 17 MHC 2019; 26 (1) 世話人会 総会 57

59 MHC 2019; 26 (1) 特別講演 HLA Killer immunoglobulin-like receptor KIR 58

60 17 MHC 2019; 26 (1) Killer immunoglobulin-like receptor KIR Natural killer NK killer immunoglobulin-like receptor KIR HLA KIR HLA NK KIR KIR Ruggeri, Science 2002 HIV AIDS KIR PCR KIR KIR KIR3DL1 HLA-B GD2 Forlenza, J Clin Oncol 2016 Boudreau, J Clin Oncol 2017 KIR KIR3DL1 Ureshino, Shindo, Cancer Immunol Res 2018 KIR KIR KIR 59

61 MHC 2019; 26 (1) シンポジウム (1) 1 HLA 2 HLA HLA 1) 2) 3) 3) 4) 1) 2) HLA 3) 4) 3 HLA 60

62 17 MHC 2019; 26 (1) 1 HLA HLA HLA HLA HLA GVHD T GVHD anti-thymogloblin ATG cyclophosphamide CY HLA GVHD super high risk GVL graft versus leukemia ATG T GVHD / GVL GVHD HLA HLA HLA full allogeneic spousal preliminary data HLA / % ATG 2.5 mg/kg tacrolimus (TAC)+ methylprednisolone (mpsl) 2 mg/kg+short-term MTX (smtx)+mycophenolate mofetil (MMF) 15 mg/kg TAC+mPSL 1 mg/kg HLA 5 62% 31% 61

63 MHC 2019; 26 (1) 17 2 HLA HLA 1) 2) 3) 3) 4) 1) 2) HLA 3) 4) graft-versus-host disease, GVHD graft-versus-leukemia effect GVL GVHD Human leukocyte antigen, HLA HLA-A, -B, -C, -DRB1 HLA 6 HLA HLA HLA- A, -B, -C, -DRB1 HLA GVHD T HLA-A, -B, -C, -DRB HLA HLA-A, -B, -C, -DRB1 8 HLA HLA HLA HLA private haplotype 0.005% 8 90% HLA 90% HLA % % HLA % % % % % % % p= DFS % % % % p= % % % % p= % % % % p= Grade II IV GVHD % % % % p=0.23 Grade III IV GVHD % % % % p=0.54 GVHD

64 17 MHC 2019; 26 (1) 36.8% % % % p=0.60 DFS PS 2 4 HR 2.54, 95%CI , vs PS 0 1 HR 0.81, 95%CI , vs TBI HR 2.21, 95%CI , vs 0 1 DFS HR 1.79, 95%CI: HLA GVHD DFS HLA GVL HLA 63

65 MHC 2019; 26 (1) 17 3 HLA HLA HLA-A, -B, -DRB1 6 2 HLA-A, -B, -C, -DRB /kg CD34 HLA HLA HLA 1 HLA 0 HLA HLA-A, -B, -C, -DRB % 82% 79% P= P= P=0.005 CD34 HLA 2 GVH Homo to hetero HLA 64

66 17 MHC 2019; 26 (1) 休憩 シンポジウム (2) HLA 1 de novo DSA 1) 2) 1) 1) 1) 1) 2) 2 3 de novo DSA 1) 2) 2) 2) 3) 3) 4) 4) 2) 2) 2) 5) 2) 1) 2) 3) 4) 5) 65

67 MHC 2019; 26 (1) 17 1 de novo DSA 1) 2) 1) 1) 1) 1) 2) HLA de novo donor specific HLA antibodies: dn DSA chronic antibody mediated rejection: chronic AMR HLA chronic AMR chronic AMR HLA subclinical HLA chronic AMR HLA 179 Flow PRA screening test LABScreen single antigen test dn DSA dn DSA dn DSA dn DSA % de novo DSA dn DSA 1 4.2% 3 8.5% % dn DSA HLA-class I +class II 7 HLA-DR DR+DQ 7 HLA-DQ chronic AMR 9 T T cell mediated rejection: TCMR +AMR 1 subclinical AMR 3 13 Chronic AMR TCMR+AMR Rituximab Subclinical AMR 4 dn DSA chronic AMR 66

68 17 MHC 2019; 26 (1) 2 CDC T-cell MFI HLA FCM HLA A, B, C, DR, DQ, DP HLA CDC FCM HLA MFI< DSA MFI CDC, FCM DSA B 2 DQ 2 CDC FCM DQ 2 FCM 1 2 AMR 2 HLA HLA A, B, DR FCM 67

69 MHC 2019; 26 (1) 17 3 de novo DSA 1) 2) 2) 2) 3) 3) 4) 4) 2) 2) 2) 5) 2) 1) 2) 3) 4) 5) HLA DSA DSA de novo DSA SAB HLA DSA 17% 38% DSA 50% F2 DSA 3% p=0.001 DSA 41.4% DSA 22.4% p=0.04 DSA DSA 34% DSA 51% DSA p=0.034 DSA p= DSA DSA p= DSA DSA DSA DSA 68

70 Major Histocompatibility Complex 2019; 26 (1): MHC I MHC MHC ES ips 2006 MHC JST J-STAGE MHC II 1 12, Microsoft Word Microsoft Word Microsoft PowerPoint Microsoft PowerPoint CDR 2 1 FAX 69

71 MHC 2019; 26 (1) Susceptibility gene for non-obstructive azoospermia in the HLA class II region: correlations with Y chromosome microdeletion and spermatogenesis. Tetsuya Takao 1), Akira Tsujimura 1), Masaharu Sada 2), Reiko Goto 2), Minoru Koga 3), Yasushi Miyagawa 1), Kiyomi Matsumiya 1), Kazuhiko Yamada 2), Shiro Takahara 1) 1) Department of Urology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan 2) Department of Regenerative Medicine, National Cardiovascular Center, Suita, Osaka, Japan 3) Department of Urology, Osaka Central Hospital, Osaka, Japan FlowPRA HLA 1) 1) 2) 2) 3) 1) 2) 3) cm, ml, g, Kg, pg, μl, %, C HLA-DRB words 5 3 Introduction Materials and Methods Results Discussion Acknowledgements Disclosures References Legend to Figures cm, ml, g, Kg, pg, μl, %, C HLA-DRB words LCT Lymphocyte cytotoxicity test 6 HP coi/index.html COI JSHI_COI COI _ 2 70

72 MHC 2019; 26 (1) Disclosures: none to declare Disclosures: received a reward for lecture from This study was conducted by a research fund from et al. 1. Shi Y, Yoshihara F, Nakahama H, et al.: A novel immunosuppressant FTY720 ameliorates proteinuria and alterations of intrarenal adrenomedullin in rats with autoimmune glomerulonephritis. Regulatory Peptides 127(1 3): , Tongio M, Abbal M, Bignon JD, et al.: ASH#18: HLA-DPB1. Genetic diversity of HLA Functional and Medical Implication (ed. Charron D), Medical and Scientific International Publisher, p , IVIG 1 17(1): 36 40, Medical View p III 1 6, Microsoft Word Microsoft Word Microsoft PowerPoint Microsoft PowerPoint CDR 2 1 FAX words IV 6,000 12,

73 MHC 2019; 26 (1) V J8 MHC Tel: Fax: words 400 words words

74 Major Histocompatibility Complex 2019; 26 (1): Instructions to Authors (updated on Feb. 19, 2019) Submission MHC is the official journal of the Japanese Society for Histocompatibility and Immunogenetics (JSHI). The aim of this journal is to serve as a forum for the scientific information in the form of original and high quality papers in the field of major histocompatibility complex (MHC) and immunogenetics. Manuscripts, from basic to clinical research relating to MHC or immunogenetics, are accepted with the understanding that they are original unpublished work and are not being submitted elsewhere. Manuscripts should be written in Japanese or English. First author and corresponding author must be members of JSHI, while it is preferable for the other co-authors also to be JSHI members. Ethics: Clinical and basic studies using human subjects and specimens obtained from humans must adhere to the 1980 Helsinki Declaration (adapted by the 18 th World Medical Assembly) and must be approved by the ethics review board of each participating institution. Furthermore, animal studies must adhere to such guidelines. Conflict of interest: All the authors must clearly declare any conflicts of interest according to the guideline of JSHI ( Further information is available upon request. Types of papers published: Original articles, reviews, series, short communications (including research and technical bulletins) and case reports are acceptable. Review: The editorial board is responsible for the acceptance of all submitted papers based on a review by multiple referees. Based on the outcome of the review, the board may request corrections, omissions, or additions for publication in MHC. Copyright: Papers that are accepted for publication become copyright of JSHI and will be made available electronically via the J-Stage platform ( Fees: There is no fee for publication. However, authors will be responsible for the costs incurred for color photographs and special prints (please specify at submission if color printing is required). Reprints: Costs incurred for reprints will be charged based on the number of copies and pages (please specify the number of reprints at the time of proofing). 73

75 MHC 2019; 26 (1) Manuscript (in English) 1. Original articles Summary Articles are limited to 4,000 words. Each figure, table, and photograph must be included on separate manuscript pages and must include a title. The location of tables and figures in the manuscript must be clearly stated in the main text. The main text must be submitted as a Microsoft Word file, tables as a Microsoft Word, Excel, or PowerPoint files, and figures and photographs as PowerPoint files. All files must be electronically sent as attached files via to the editor-in-chief. If the authors would like to submit large size files (over 30 MB), the files should be saved on a CD-ROM, which is to be submitted by mail to the editor-in-chief with one printed copies of the manuscript. Alternatively, the large size files may be submitted via a high volume file transfer service. In that case, the authors must contact the editorial office (indicated on the last page of this instruction) before submission. First page The first page is the title page, which must clearly state that the submitted article is an "Original article" and include titles, and the name and affiliation of each author. Include the address, name, telephone number, fax number, and address of corresponding author at the bottom of the title page. Follow the example shown below for the title, author names, and affiliations: Susceptibility gene for non-obstructive azoospermia in the HLA class II region: correlations with Y chromosome microdeletion and spermatogenesis. Tetsuya Takao 1), Akira Tsujimura 1), Masaharu Sada 2), Reiko Goto 2), Minoru Koga 3), Yasushi Miyagawa 1), Kiyomi Matsumiya 1), Kazuhiko Yamada 2), Shiro Takahara 1) 1) Department of Urology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan 2) Department of Regenerative Medicine, National Cardiovascular Center, Suita, Osaka, Japan 3) Department of Urology, Osaka Central Hospital, Osaka, Japan Main text - The second page must contain an "Abstract" no more than 250 words in length, followed by key words (no more than five). 74

76 MHC 2019; 26 (1) - Starting on the third page, the main text begins with the "Introduction" and is followed by the "Materials and Methods", "Results", "Discussion", Acknowledgments, Conflict of Interest, and "References" sections, in this order. - Geographic, human, and scientific names are listed in their original languages. Use generic names for drugs with commercial names in parentheses. - Indicate units and quantities using Arabic numbers followed by international units (cm, ml, g, kg, pg, l, %, C, etc.). References References should include names of authors (last names first); title of article; title of journal (abbreviate according to the style of Index Medicus) or book; volume number; location and name of publishing company (book only); first page, year of publication. For references with more than three authors, list the first three, followed by "et al.". See the examples below: Journal. Shi Y, Yoshihara F, Nakahama H, et al.: A novel immunosuppressant FTY720 ameliorates proteinuria and aiterations of intrarenal adrenomedullin in rats with autoimune glomerulonephritis. Regulatory Peptides 127: , Book. Katz DH: Lymphocyte Differentiation, Recognition, and Regulation. New York, Academic Press, 1997 Chapter in a book. Tongio M, Abbal M, Bignon JD, et al. ASH#18 : HLA-DPB1. Charron D (ed): Genetic diversity of HLA Functional and Medical Implication. Paris, EDK, Short communications (including research and technical bulletins) and Case reports Summary Short communications are limited to 1,500 words. For other information, please see Summary section of Original articles described before. 75

77 MHC 2019; 26 (1) First page The first page is the title page, which must clearly state that the submitted article is a "Short Communication" or "Case report" and include titles and the name and affiliation of each author. Include the address, name, telephone number, fax number, and address of the corresponding author at the bottom of the title page. Follow the example shown below for the title, author names, and affiliations: Main text - Short communications and case reports do not require an abstract. - After the second page, follow the same guidelines for the third and subsequent pages of original articles as described. 3. Reviews, Series, and Others As a general rule, reviews and series are written by invitation from the editorial board; however, submission by JSHI members is strongly encouraged. The editorial board determines the total number of pages, but in general a manuscript of no more than 3,000 words is preferable. As a general rule, reviews and series follow the format for original articles. Editorial Office and Mailing Address Manuscripts should be submitted to the Editor-in-Chief at the Editorial office: Editor-in-Chief: Prof. Akinori Kimura Editorial office: The Japanese Society for Histocompatibility and Immunogenetics Journal, MHC c/o Department of Advanced Technology for Transplantation J8, Faculty of Medicine, Graduate School of Medicine, Osaka University 2-2 Yamadaoka, Suita, Osaka , Japan Tel: Fax:

78 MHC 2019; 26 (1) MHC MHC ips MHC HLA URL URL umin.ac.jp/ Tel Fax FAX

Major Histocompatibility Complex 2019; 26 (1): MHC I MHC MHC ES ips 2006 MHC JST J-STAGE MHC II 1 12, Microso

Major Histocompatibility Complex 2019; 26 (1): MHC I MHC MHC ES ips 2006 MHC JST J-STAGE MHC II 1 12, Microso Major Histocompatibility Complex 2019; 26 (1): 69 72 MHC 2019 2 12 I MHC MHC 1964 18 2013 ES ips 2006 MHC JST J-STAGE MHC II 1 12,000 12 1 400 Microsoft Word Microsoft Word Microsoft PowerPoint Microsoft

More information

16 MHC 2018; 25 (1) 参加費 1 2, , ,000 会議等 :00 13: :00 13: :20 会場地図 TEL JR 350 m 57

16 MHC 2018; 25 (1) 参加費 1 2, , ,000 会議等 :00 13: :00 13: :20 会場地図 TEL JR 350 m 57 Major Histocompatibility Complex 2018; 25 (1): 56 82 抄録集 16 2018 3 3 7 2 4 43 TEL 06 6962 7001 594 1101 840 TEL 0725 56 1220 56 16 MHC 2018; 25 (1) 参加費 1 2,000 2 1,000 3 3,000 会議等 1 3 3 13:00 13:10 2 3

More information

MHC 2013; 20 ( 2 QC QC DNA-QC 3. QCWS 集会参加および参加証明書発行 QCWS QCWS QCWS 解析方法 DNA-QC Luminex SSO SSO SSP SBT QC FlowPRA Lab Screen WAK Flow ICFA 4 HL

MHC 2013; 20 ( 2 QC QC DNA-QC 3. QCWS 集会参加および参加証明書発行 QCWS QCWS QCWS 解析方法 DNA-QC Luminex SSO SSO SSP SBT QC FlowPRA Lab Screen WAK Flow ICFA 4 HL Major Histocompatibility Complex 2013; 20 (: 13 16 QCWS # 1. ワークショップの経過 24 1 QCWS HP QCWS 24 2 57 DNA-QC 53 QC 38 1 20 QCWS DNA-QC QC 4 QCWS 4 4 4 16 QCWS 5 21 57 DNA-QC 53 QC 37 5 6 7 HP 8 25 HP 2. QCWS

More information

Major Histocompatibility Complex 2017; 24 (3): II MHC MHC Precision Medicine HLA personalized medicine precision medicine

Major Histocompatibility Complex 2017; 24 (3): II MHC MHC Precision Medicine HLA personalized medicine precision medicine 24 3 29 12 20 27 171 30 172 22 HLA-QC 175 30 HLA 182 183 30 HLA 190 30 192 30 HLA 194 29 HLA 196 29 HLA 198 J.J. van Rood 215 16 217 28 219 MHC 28 2 1 220 223 Major Histocompatibility Complex Official

More information

MHC 2013; 20 (1) 11 参加費 1 2, , ,000 会議等 :50 14: :30 13: :00 会場地図 参天製薬株式会社本社案内図 TEL 新大阪駅より

MHC 2013; 20 (1) 11 参加費 1 2, , ,000 会議等 :50 14: :30 13: :00 会場地図 参天製薬株式会社本社案内図 TEL 新大阪駅より Major Histocompatibility Complex 2013; 20 (1): 63 89 抄録集 11 2013 2 2 3 9 19 TEL: 06 6321 7000 630 0293 1248 1 TEL: 0743 77 0880 E-mail: tubaki@nara.med.kindai.ac.jp 63 MHC 2013; 20 (1) 11 参加費 1 2,000 2

More information

Major Histocompatibility Complex 2018; 25 (2): 抄録集 2 HLA A 3 128

Major Histocompatibility Complex 2018; 25 (2): 抄録集 2 HLA A 3 128 Major Histocompatibility Complex 2018; 25 (: 128 138 抄録集 2018 4 14 A 3 128 MHC 2018; 25 ( HLA 2013 10.5 10 8 12 10 8 2016 CD34 + HLA NC 10 8 CD34 + CD34 + 10 6 NC10.5 2013.Apr 2014.Mar NC11 2014.Apr 2016.Jun

More information

20-第14回抄録集.indd

20-第14回抄録集.indd Major Histocompatibility Complex 2016; 23 (1): 45 71 抄録集 14 2016 2 6 7 2 4 43 TEL 06 6962 7001 HLA 600 8813 134 1 2F TEL 075 313 5201 FAX 075 313 5202 E-mail:hla@hla.or.jp 45 MHC 2016; 23 (1) 第 14 回日本組織適合性学会近畿地方会

More information

1 HLA MHC 2017; 24 (2) HLA HLA 1967 HLA HLA HLA HLA 1980 HLA HLA ABO HLA 2000 HLA DSA 2010 HLA HLA HLA HLA HLA HLA HLA HLA HLA GVHD HLA HLA

1 HLA MHC 2017; 24 (2) HLA HLA 1967 HLA HLA HLA HLA 1980 HLA HLA ABO HLA 2000 HLA DSA 2010 HLA HLA HLA HLA HLA HLA HLA HLA HLA GVHD HLA HLA Major Histocompatibility Complex 2017; 24 (2): 150 157 抄録集 1 HLA 2017 5 13 150 1 HLA MHC 2017; 24 (2) HLA 1960 1964 HLA 1967 HLA HLA HLA HLA 1980 HLA HLA ABO HLA 2000 HLA DSA 2010 HLA HLA HLA HLA HLA HLA

More information

DynalTransplantDiagnostic.indd

DynalTransplantDiagnostic.indd 2011 1 SeCore HLA SBT 1 2 AllSet + Gold SSP HLA 7 3 SSP UniTray HLA 11 4 27 5 32 ii 1 SeCore HLA SBT SeCore 2 SeCore HLA SBT SeCore 3 SeCore 4 HLA-I 5 HLA-II 5 utype 5 GSSP 6 1 SeCore HLA SBT Sequencing

More information

日本組織適合性学会誌MHCの投稿規定

日本組織適合性学会誌MHCの投稿規定 投稿 執筆規定 (2019 年 2 月 12 日改訂 ) I. 概要内容 : MHC に関する基礎研究から臨床研究まで全てを対象にし, 未発表の論文, 他誌に投稿中 ( もしくは掲載予定 ) でないものに限る 資格 : 筆頭著者および責任著者は本学会会員であり, その他の共著者も, 原則として, 本学会会員に限る ただし,MHC 編集委員会が非会員に執筆を依頼した総説については, その限りでない 倫理

More information

日本組織適合性学会誌第20巻2号

日本組織適合性学会誌第20巻2号 Major Histocompatibility Complex 2013; 20 (2): 121 129 平成 25 年度認定 HLA 検査技術者講習会テキスト HLA 1) 1) HLA HLA HLA PRA Panel reactive antibody DSA Donor specific alloantibody class subclass non-hla HLA キーワード :Human

More information

スライド 1

スライド 1 Flow PRA 法の検査状況の解析 福岡赤十字病院 検査部 移植検査課 / 輸血細胞治療部 金本人美 参加施設数 -Flow PRA- Screening ClassⅠ 25 施設 ClassⅡ 24 施設 Single antigen ClassⅠ 2 施設 ClassⅡ 2 施設 18th 17th Screening ClassⅠ 22 施設 ClassⅡ 20 施設 Single antigen

More information

22 S2-4 教育講演 ( 認定制度講習会 ) 9 月 14( 土 ) 10:00 ~ 12:00 座長 EL-1 EL-2 EL-3 HLA 1,2) 1) 2) HLA HLA 17th QC ワークショップ集会 9 月 14 日 ( 土 ) 13:00 ~ 16:00 タイピング結果解析 1

22 S2-4 教育講演 ( 認定制度講習会 ) 9 月 14( 土 ) 10:00 ~ 12:00 座長 EL-1 EL-2 EL-3 HLA 1,2) 1) 2) HLA HLA 17th QC ワークショップ集会 9 月 14 日 ( 土 ) 13:00 ~ 16:00 タイピング結果解析 1 22 特別講演 Ⅰ 9 月 15 日 ( 日 ) 13:40 ~ 14:40 座長 SL-1 ips 特別講演 Ⅱ( スポンサード ランチ付き ) 9 月 16 日 ( 月 ) 12:00 ~ 13:00 座長 SL-2 HLA シンポジウム Ⅰ 9 月 15 日 ( 日 ) 14:40 ~ 16:40 免疫寛容を誘導する養子免疫療法 : その基礎と臨床応用 座長 S1-1 CREST JST S1-2

More information

スライド 1

スライド 1 抗体検査結果解析 (HP 掲載用 ) その他検査法およびクロスマッチ 日本赤十字社中央血液研究所中島文明 その他検査法 ダイレクト クロスマッチ 定 義 その他抗体検査 FlowPRA, LABScreen, WAKFlow 以外の HLA 抗体検査において SH0~SH04 の 4 サンプルを対象としていること ダイレクト クロスマッチ, FCM, ICFAなどクロスマッチ可能な検査方法において

More information

Microsoft PowerPoint - WAK Flow H20 [互換モード]

Microsoft PowerPoint - WAK Flow H20 [互換モード] 蛍光ビーズを用いた HLA 抗体検査試薬の解析結果 WAKFlow HLA 抗体クラス Ⅰ&Ⅱ(MR) 平成 2 年 9 月 19 日 QC ワークショップ WAKFlow HLA 抗体クラス Ⅰ&Ⅱ(MR) について パネル細胞の選択 対象抗原 クラス Ⅰ: 日本人における遺伝子頻度が 1% 以上の HLA-A または -B 抗原 クラス Ⅱ:HLA-DR および DQ 座の公認抗原 選択条件 クラス

More information

日本組織適合性学会誌第23巻2号

日本組織適合性学会誌第23巻2号 Major Histocompatibility Complex 2016; 23 (2): 115 122 HLA 1 1) 1) HLA MHC 1900 HLA HLA キーワード : HLA HLA HLA HLA 2 HLA HLA HLA 3 1 1 HLA HLA 図 1 2016 6 30 2016 8 2 105 0013 1 10 14 3 5 TEL: 03 5776 0048

More information

MHC23-3

MHC23-3 Major Histocompatibility Complex 2016; 23 (3): 168 184 1) 2) 3) 4) 5) 1) 6) 7) 8) 1) 2) 3) 4) HLA 5) 6) 7) 8) HLA 11 25 28 10 22 1 4 61 44 6 1 10 11 5 HLA 60 3 27 3 5 9 5 10 19 5 50 22.4 5.9 8.2% 78.7%

More information

udc-2.dvi

udc-2.dvi 13 0.5 2 0.5 2 1 15 2001 16 2009 12 18 14 No.39, 2010 8 2009b 2009a Web Web Q&A 2006 2007a20082009 2007b200720082009 20072008 2009 2009 15 1 2 2 2.1 18 21 1 4 2 3 1(a) 1(b) 1(c) 1(d) 1) 18 16 17 21 10

More information

IR0036_62-3.indb

IR0036_62-3.indb 62 3 2016 253 272 1921 25 : 27 8 19 : 28 6 3 1921 25 1921 25 1952 27 1954 291960 35 1921 25 Ⅰ 0 5 1 5 10 14 21 25 34 36 59 61 6 8 9 11 12 16 1921 25 4 8 1 5 254 62 3 2016 1 1938.8 1926 30 1938.6.23 1939.9

More information

untitled

untitled Copyright - Zac Poonen (1999) This book has been copyrighted to prevent misuse. It should not be reprinted or translated without written permission from the author. Permission is however given for any

More information

2 10 The Bulletin of Meiji University of Integrative Medicine 1,2 II 1 Web PubMed elbow pain baseball elbow little leaguer s elbow acupun

2 10 The Bulletin of Meiji University of Integrative Medicine 1,2 II 1 Web PubMed elbow pain baseball elbow little leaguer s elbow acupun 10 1-14 2014 1 2 3 4 2 1 2 3 4 Web PubMed elbow pain baseball elbow little leaguer s elbow acupuncture electric acupuncture 2003 2012 10 39 32 Web PubMed Key words growth stage elbow pain baseball elbow

More information

大学論集第42号本文.indb

大学論集第42号本文.indb 42 2010 2011 3 279 295 COSO 281 COSO 1990 1 internal control 1 19962007, Internal Control Integrated Framework COSO COSO 282 42 2 2) the Committee of Sponsoring Organizations of the Treadway committee

More information

Unknown

Unknown Journal of Breast and Thyroid Sonology Journal of Breast and Thyroid Sonology Vol.2, No.3 July 2013 Report The 30 th Meeting of Japan Association of Breast and Thyroid Sonology... 1 Department of Organ

More information

JR09報告ファイル

JR09報告ファイル 第 2 回関東 HLA 研究会学術集会 ワークショップ 蛍光ビーズ法 HLA 抗体検査試薬の 半量法に関するワークショップ 中島文明 日本赤十字社中央血液研究所研究開発部 2018 年 6 月 9 日 ( 土 ) 東京大学本郷キャンパス医学部 1 号館 3 階講堂 序 論 昨年 公表された論文では LABScreen Single Antigen(LS-SA) 試薬について操作全体の効率化を検討し約

More information

Studies of Foot Form for Footwear Design (Part 9) : Characteristics of the Foot Form of Young and Elder Women Based on their Sizes of Ball Joint Girth

Studies of Foot Form for Footwear Design (Part 9) : Characteristics of the Foot Form of Young and Elder Women Based on their Sizes of Ball Joint Girth Studies of Foot Form for Footwear Design (Part 9) : Characteristics of the Foot Form of Young and Elder Women Based on their Sizes of Ball Joint Girth and Foot Breadth Akiko Yamamoto Fukuoka Women's University,

More information

,,,,., C Java,,.,,.,., ,,.,, i

,,,,., C Java,,.,,.,., ,,.,, i 24 Development of the programming s learning tool for children be derived from maze 1130353 2013 3 1 ,,,,., C Java,,.,,.,., 1 6 1 2.,,.,, i Abstract Development of the programming s learning tool for children

More information

JC オンライン投稿の操作方法について(mac) 2011_9 FINAL

JC オンライン投稿の操作方法について(mac) 2011_9 FINAL Journal of Cardiology Journal of Cardiology Cases < > Elsevier Editorial System > > Journal of Cardiology.. http://ees.elsevier.com/jjcc Journal of Cardiology Cases http://ees.elsevier.com/jccase Guide

More information

22-1.indb

22-1.indb Major Histocompatibility Complex 2015; 22 (1): 44 66 抄録集 13 2015 2 7 7 2 4 43 TEL: 06 6962 7001 589 8511 377 2 TEL: 072 366 0221 E-mail: yuketsu@med.kindai.ac.jp 44 MHC 2015; 22 (1) 第 13 回日本組織適合性学会近畿地方会

More information

8 The Bulletin of Meiji University of Integrative Medicine API II 61 ASO X 11 7 X-4 6 X m 5 X-2 4 X 3 9 X 11 7 API 0.84 ASO X 1 1 MR-angio

8 The Bulletin of Meiji University of Integrative Medicine API II 61 ASO X 11 7 X-4 6 X m 5 X-2 4 X 3 9 X 11 7 API 0.84 ASO X 1 1 MR-angio 7-14 2010 1 1 1 2 1 1 1 2 Fontaine II ASO61 3 API ASO ASO ASO API API KKKKKKKKKK ASO Fontaine II API Received April 14, 2009; Accepted July 16, 2009 I arteriosclerosis obliterans: ASO ASO 50 70 1,2 Fontaine

More information

スライド 1

スライド 1 DNAタイピング結果解析 HP掲載用 試料説明 日本赤十字社 九州ブロック血液センター 黒田 ゆかり 22nd DNA-QCサンプル 購入した細胞から抽出したDNAを4サンプル配布 ルミネックスSSO法用の陰性コントロール DNase free water を配布 配布サンプル Sample ID (Cap Color) a.dna Label Color H31 H32 H33 Volume Label

More information

JOURNAL OF THE JAPANESE ASSOCIATION FOR PETROLEUM TECHNOLOGY VOL. 66, NO. 6 (Nov., 2001) (Received August 10, 2001; accepted November 9, 2001) Alterna

JOURNAL OF THE JAPANESE ASSOCIATION FOR PETROLEUM TECHNOLOGY VOL. 66, NO. 6 (Nov., 2001) (Received August 10, 2001; accepted November 9, 2001) Alterna JOURNAL OF THE JAPANESE ASSOCIATION FOR PETROLEUM TECHNOLOGY VOL. 66, NO. 6 (Nov., 2001) (Received August 10, 2001; accepted November 9, 2001) Alternative approach using the Monte Carlo simulation to evaluate

More information

News_Letter_No35(Ver.2).p65

News_Letter_No35(Ver.2).p65 OCIAL AFETY CIENCE No.35 2000.8 from Institute of Social Safety Science 10 11 17 11 19 17 181819 18 420-0042 5-9-1 JR 25 Tel 054-251-7100-1 - 10 10 I (1) 12 11 17 19 (2) 5-9-1 JR 25 II (1) 12 9 18 (2)

More information

MHC Vol. 19, No 日本組織適合性学会誌 MHC の投稿規定 I. 投稿について内容 :MHC に関する基礎研究から臨床研究まで全てを対象にし, 未発表の論文, 他誌に投稿中でないものに限る 資格 : 著者 ( 共著者を含む ) は原則として本学会会員に限る 倫理 : ヒト

MHC Vol. 19, No 日本組織適合性学会誌 MHC の投稿規定 I. 投稿について内容 :MHC に関する基礎研究から臨床研究まで全てを対象にし, 未発表の論文, 他誌に投稿中でないものに限る 資格 : 著者 ( 共著者を含む ) は原則として本学会会員に限る 倫理 : ヒト 223 日本組織適合性学会誌 MHC の投稿規定 I. 投稿について内容 :MHC に関する基礎研究から臨床研究まで全てを対象にし, 未発表の論文, 他誌に投稿中でないものに限る 資格 : 著者 ( 共著者を含む ) は原則として本学会会員に限る 倫理 : ヒトおよびヒトの試料を用いた臨床研究 基礎研究の場合,1980 年ヘルシンキ宣言 ( 第 18 回 World Medical Assembly

More information

Microsoft Word - PCM TL-Ed.4.4(特定電気用品適合性検査申込のご案内)

Microsoft Word - PCM TL-Ed.4.4(特定電気用品適合性検査申込のご案内) (2017.04 29 36 234 9 1 1. (1) 3 (2) 9 1 2 2. (1) 9 1 1 2 1 2 (2) 1 2 ( PSE-RE-101/205/306/405 2 PSE-RE-201 PSE-RE-301 PSE-RE-401 PSE-RE-302 PSE-RE-202 PSE-RE-303 PSE-RE-402 PSE-RE-203 PSE-RE-304 PSE-RE-403

More information

スライド 1

スライド 1 1 抗体部門の解析について 19thQCWS から抗体解析結果の内容を! 変更点 1. サンプルの性状についての解説を追加した 2. 方法別の判定表は廃止し これまで以上に測定データの差異に拘って解析した 3. 集会での報告の順番を変更した 最初に今年度の総評および問題点を提議する 其々の問題点について検査方法に即して解析し ディスカッションの場を提供する 2 総合解析の内容 参加状況 施設別結果評価

More information

MHC Vol. 19, No 平成 23 年度 日本組織適合性学会 決算報告書 自 平成 23 年 4 月 1 日 至 平成 24 年 3 月 31 日 収入の部 予算 円 決算 円 会 員 年 会 費 3,000,000 3,275, ,000 学 会 誌 広 告 費

MHC Vol. 19, No 平成 23 年度 日本組織適合性学会 決算報告書 自 平成 23 年 4 月 1 日 至 平成 24 年 3 月 31 日 収入の部 予算 円 決算 円 会 員 年 会 費 3,000,000 3,275, ,000 学 会 誌 広 告 費 MHC Vol. 19, No. 3 279 平成 23 年度 日本組織適合性学会 決算報告書 自 平成 23 年 4 月 1 日 至 平成 24 年 3 月 31 日 収入の部 予算 円 決算 円 会 員 年 会 3,, 3,275, 275, 学 会 誌 広 告 8, 6, 2, 学 会 誌 販 売 等 1, 51,895 48,15 QC ワークショップ 424, 539, 115, 講 習

More information

05_藤田先生_責

05_藤田先生_責 This report shows innovation of competency of our faculty of social welfare. The aim of evaluation competency is improvement in the Social welfare education effects, by understanding of studentʼs development

More information

soturon.dvi

soturon.dvi 12 Exploration Method of Various Routes with Genetic Algorithm 1010369 2001 2 5 ( Genetic Algorithm: GA ) GA 2 3 Dijkstra Dijkstra i Abstract Exploration Method of Various Routes with Genetic Algorithm

More information

semen quality or those without WBC in semen. In the patients with azoospermia and normal FSH levels (normogonadotropic azzospermia), the antibody (IgG

semen quality or those without WBC in semen. In the patients with azoospermia and normal FSH levels (normogonadotropic azzospermia), the antibody (IgG CLINICAL STUDIES OF UROGENITAL INFECTIONS WITH CHLAMYDIA TRACHOMA TIS Report 2. The Epidemiology of Chlamydial Infections in Okayama District in Japan and Detection of Antibodies to Chlamydiae in the Sera

More information

JJRM5005/04.短報.責了.indd

JJRM5005/04.短報.責了.indd Jpn J Rehabil Med 2013 ; : 319.327 1 2 3 4 5 6 Survey of the Electronic Medical Recoding System Used in Kaifukuki Rehabilitation Wards Hidekazu SUGAWARA, 1 Tetsutaro YAHATA, 2 Hideto OKAZAKI, 3 Mitsuhiro

More information

スライド 1

スライド 1 部門別解析および結果評価 - 抗体検査 - 日本赤十字社近畿ブロック血液センター高陽淑 参加状況 1. 参加施設の構成 2. 抗体検査実施状況 報告の内容 抗体検査の結果評価 1. 部門別総合判定結果 ( 抗体検出 特異性同定 ) 2. 方法間 施設間の結果比較 3. 部門別評価結果 ( 抗体検出 特異性同定 ) まとめ 1. 17thQCWS 抗体検査に関する講評 2. 18thQCWSに向けて

More information

202

202 201 Presenteeism 202 203 204 Table 1. Name Elements of Work Productivity Targeted Populations Measurement items of Presenteeism (Number of Items) Reliability Validity α α 205 α ä 206 Table 2. Factors of

More information

特集・総説(44行)/P429~437_特集 田中(4C)

特集・総説(44行)/P429~437_特集 田中(4C) 429 Donor specific HLA antibodies for organ transplantation HLA Foundation Laboratory Hidenori TANAKA Summary Donor-specific Antibodies DSAs are risk factors for rejection and graft loss in solid organ

More information

Web of Scienceの使い方. 2004年12月版

Web of Scienceの使い方. 2004年12月版 Title Web of Science の使い方 Author(s) 北海道大学附属図書館参考調査係 Issue Date 2004 Doc URL http://hdl.handle.net/2115/360 Rights(URL) http://creativecommons.org/licenses/by-nc-sa/2.1/jp/ Type learningobject Note ライブラリーセミナー

More information

Title 泌尿器科領域に於ける17-Ketosteroidの研究 17-Ketosteroidの臨床的研究 第 III 篇 : 尿 Author(s) 卜部, 敏入 Citation 泌尿器科紀要 (1958), 4(1): 3-31 Issue Date URL

Title 泌尿器科領域に於ける17-Ketosteroidの研究 17-Ketosteroidの臨床的研究 第 III 篇 : 尿 Author(s) 卜部, 敏入 Citation 泌尿器科紀要 (1958), 4(1): 3-31 Issue Date URL Title 泌尿器科領域に於ける17-Ketosteroidの研究 17-Ketosteroidの臨床的研究 第 III 篇 : 尿 Author(s) 卜部, 敏入 Citation 泌尿器科紀要 (1958), 4(1): 3-31 Issue Date 1958-01 URL http://hdl.handle.net/2433/111559 Right Type Departmental Bulletin

More information

Bull. of Nippon Sport Sci. Univ. 47 (1) Devising musical expression in teaching methods for elementary music An attempt at shared teaching

Bull. of Nippon Sport Sci. Univ. 47 (1) Devising musical expression in teaching methods for elementary music An attempt at shared teaching Bull. of Nippon Sport Sci. Univ. 47 (1) 45 70 2017 Devising musical expression in teaching methods for elementary music An attempt at shared teaching materials for singing and arrangements for piano accompaniment

More information

Title 生活年令による学級の等質化に関する研究 (1) - 生活年令と学業成績について - Author(s) 与那嶺, 松助 ; 東江, 康治 Citation 研究集録 (5): 33-47 Issue Date 1961-12 URL http://hdl.handle.net/20.500.12000/ Rights 46 STUDIES ON HOMOGENEOUS

More information

特集・総説(44行)/P494~504_総説 佐治(4C)

特集・総説(44行)/P494~504_総説 佐治(4C) 494 Vol. 45, No. 5 HLA HLA HLA Transplantation and HLA antibody: posttransplantation HLA antibody monitoring and HLA type & screen to overcome technical and logistic limitations Hiroh SAJI HLA Laboratory,

More information

;~ (Summary) The Study on the Effects of Foot Bathing on Urination Kumiko Toyoda School of Human Nursing, University of Shiga Prefecture Background Foot bathing is one of the important nursing care for

More information

Juntendo Medical Journal

Juntendo Medical Journal * Department of Health Science Health Sociology Section, Juntendo University School of Health and Sports Science, Chiba, Japan (WHO: Ottawa Charter for Health promotion, 1986.) (WHO: Bangkok Charter

More information

ACS電子ジャーナル利用マニュアル

ACS電子ジャーナル利用マニュアル American Chemical Society ACS Web Edition & Journal Archives American Chemical Society ACS 4 Web Edition 2002 7 1879 Journal Archives ACS 1...2 2 2-1...3 2-2...4 2-3...5 3 3-1 Abstract...6 3-2 Full Text

More information

A B C B C ICT ICT ITC ICT

A B C B C ICT ICT ITC ICT ICT Development of curriculum for improving of teachers ICT based on evaluation standards. Kazuhiko ISHIHARA Abstract Ministry of Education and Science announced Checklist of teacher s ICT in March,. All

More information

21 Effects of background stimuli by changing speed color matching color stimulus

21 Effects of background stimuli by changing speed color matching color stimulus 21 Effects of background stimuli by changing speed color matching color stimulus 1100274 2010 3 1 ,.,,.,.,.,,,,.,, ( FL10N-EDL). ( 10cm, 2cm),,, 3.,,,, 4., ( MSS206-402W2J), ( SDM496)., 1200r/min,1200r/min

More information

阿部Doc

阿部Doc Bulletin of Osaka University of Pharmaceutical Sciences 1 (2007) Articles Medical Reform and Medical Service Market for Restructuring of the Community Medical System Isao ABE Osaka University of Pharmaceutical

More information

06’ÓŠ¹/ŒØŒì

06’ÓŠ¹/ŒØŒì FD. FD FD FD FD FD FD / Plan-Do-See FD FD FD FD FD FD FD FD FD FD FD FD FD FD JABEE FD A. C. A B .. AV .. B Communication Space A FD FD ES FD FD The approach of the lesson improvement in Osaka City University

More information

52-2.indb

52-2.indb Jpn. J. Health Phys., 52 (2) 55 60 (2017) DOI: 10.5453/jhps.52.55 * 1 * 2 * 2 * 3 * 3 2016 10 28 2017 3 8 Enhancement of Knowledge on Radiation Risk Yukihiko KASAI,* 1 Hiromi KUDO,* 2 Masahiro HOSODA,*

More information

2006 [3] Scratch Squeak PEN [4] PenFlowchart 2 3 PenFlowchart 4 PenFlowchart PEN xdncl PEN [5] PEN xdncl DNCL 1 1 [6] 1 PEN Fig. 1 The PEN

2006 [3] Scratch Squeak PEN [4] PenFlowchart 2 3 PenFlowchart 4 PenFlowchart PEN xdncl PEN [5] PEN xdncl DNCL 1 1 [6] 1 PEN Fig. 1 The PEN PenFlowchart 1,a) 2,b) 3,c) 2015 3 4 2015 5 12, 2015 9 5 PEN & PenFlowchart PEN Evaluation of the Effectiveness of Programming Education with Flowcharts Using PenFlowchart Wataru Nakanishi 1,a) Takeo Tatsumi

More information

Radiation induced colour centres in vitreous systems Stevels, J.M. Published in: Yogyo Kyokaishi Gepubliceerd: 01/01/1967 Document Version Uitgevers PDF, ook bekend als Version of Record Please check the

More information

2 The Bulletin of Meiji University of Integrative Medicine 3, Yamashita 10 11

2 The Bulletin of Meiji University of Integrative Medicine 3, Yamashita 10 11 1-122013 1 2 1 2 20 2,000 2009 12 1 2 1,362 68.1 2009 1 1 9.5 1 2.2 3.6 0.82.9 1.0 0.2 2 4 3 1 2 4 3 Key words acupuncture and moxibustion Treatment with acupuncture, moxibustion and Anma-Massage-Shiatsu

More information

大学野球の期分けにおける一般的準備期のランニング トレーニングが試合期の大学生投手の実戦状況下 パフォーマンスに与える影響

大学野球の期分けにおける一般的準備期のランニング トレーニングが試合期の大学生投手の実戦状況下 パフォーマンスに与える影響 The Effect of Pre-Season Running Training for Game Performance of University Baseball Pitcher AKAIKE, Kohei This paper provides useful information for university baseball players and coaches as well as

More information

外国語学部 紀要30号(横書)/03_菊地俊一

外国語学部 紀要30号(横書)/03_菊地俊一 Information Technology: IT e-learning e-japan e-japan e-japan IT IT IT IT IT IT e-japan e-japan e-japan e-japan e-japan e-japan IT e-japan e-japan e-japan e-japan IIe-Japan e-japan II e-japan IT e-japan

More information

2002 31 3 4 5 6 10 12 15 1 18 19 20 1

2002 31 3 4 5 6 10 12 15 1 18 19 20 1 2002 31 3 4 5 6 10 12 15 1 18 19 20 1 2002 31 2 21 NATO 22 NATO 23 1 24 25 26 27 2 Soviet Industrial Location: A Reexamination 28 29 Department of History and Classics, University of Alberta 30 31 2 2002

More information

The Journal of the Japan Academy of Nursing Administration and Policies Vol 7, No 2, pp 19 _ 30, 2004 Survey on Counseling Services Performed by Nursi

The Journal of the Japan Academy of Nursing Administration and Policies Vol 7, No 2, pp 19 _ 30, 2004 Survey on Counseling Services Performed by Nursi The Journal of the Japan Academy of Nursing Administration and Policies Vol 7, No 2, pp 19 _ 30, 2004 Survey on Counseling Services Performed by Nursing Professionals for Diabetic Outpatients Not Using

More information

untitled

untitled 2003 1924 13 1951 1979 2001 10 1977 1985 JICA 2003 1 4 200 2004 12 1 2006 7 6 2007 12 6 13 2003 4 1,612 150 2004 2009 150 13 2003 4 2004 3 1,612 48 742 156 150 4 A D A B A001 C D A B C D C D 2010 8 001

More information

スライド 1

スライド 1 1 2006 msv 2 2011 3 CT 2011 10mSv 10 40mSv 4 2012 217mSv 5 (CT) 2012 50 60mSv 6 2012 510mSv BRCA25 310 10mSv3% BRCA60-280% 3 5m Sv 1m Sv 12% . http://www.rea.or.jp/ire/pdf/report4.pdf 1.10 20 SMR 1.00

More information

29 28 39 1936 Acquiring technique and forming character in physical education after 1936 Analysis of articles of Kenji Shinozaki FUJIKAWA Kazutoshi The United Graduate School of Education Tokyo Gakugei

More information

EVALUATION OF NOCTURNAL PENILE TUMESCENCE (NPT) IN THE DIFFERENTIAL DIAGNOSIS OF IMPOTENCE Masaharu Aoki, Yoshiaki Kumamoto, Kazutomi Mohri and Kazunori Ohno Department of Urology, Sapporo Medical College

More information

How to read the marks and remarks used in this parts book. Section 1 : Explanation of Code Use In MRK Column OO : Interchangeable between the new part

How to read the marks and remarks used in this parts book. Section 1 : Explanation of Code Use In MRK Column OO : Interchangeable between the new part Reservdelskatalog MIKASA MVB-85 rullvibrator EPOX Maskin AB Postadress Besöksadress Telefon Fax e-post Hemsida Version Box 6060 Landsvägen 1 08-754 71 60 08-754 81 00 info@epox.se www.epox.se 1,0 192 06

More information

{.w._.p7_.....\.. (Page 6)

{.w._.p7_.....\.. (Page 6) 1 1 2 1 2 3 3 1 1 8000 75007000 4 2 1493 1 15 26 5 6 2 3 5 7 17 8 1614 4 9 7000 2 5 1 1542 10 11 1592 12 1614 1596 1614 13 15691615 16 16 14 15 6 2 16 1697 17 7 1811 18 19 20 1820 21 1697 22 1 8 23 3 100

More information

indd

indd 24 61 1 2011 調査 研究 1 2 1 1 2 4 1 3 4 1 2 1 2 1 2 1 2 2 1 1 2 3 4 2010 11 11 2011 1 7 Infection Control in an Endoscopy Room Multi - society Guideline and Current Status at Fukushima Medical University

More information

How to read the marks and remarks used in this parts book. Section 1 : Explanation of Code Use In MRK Column OO : Interchangeable between the new part

How to read the marks and remarks used in this parts book. Section 1 : Explanation of Code Use In MRK Column OO : Interchangeable between the new part Reservdelskatalog MIKASA MT65H vibratorstamp EPOX Maskin AB Postadress Besöksadress Telefon Fax e-post Hemsida Version Box 6060 Landsvägen 1 08-754 71 60 08-754 81 00 info@epox.se www.epox.se 1,0 192 06

More information

生研ニュースNo.132

生研ニュースNo.132 No.132 2011.10 REPORTS TOPICS Last year, the Public Relations Committee, General Affairs Section and Professor Tomoki Machida created the IIS introduction video in Japanese. As per the request from Director

More information

/ p p

/ p p http://alce.jp/journal/ 14 2016 pp. 33-54 ISSN 2188-9600 * 3 Copyright 2016 by Association for Language and Cultural Education 1 2012 1 1 * E-mail: mannami.eri@gmail.com 33 1980 1990 2012 1998 1991/1993

More information

01社会学部研究紀要.indd

01社会学部研究紀要.indd Pareto s Social System Theory Reconsidered () The equilibrium of Social System in History Makoto AKASAKA Abstract A purpose of this article is to draw exactly a summary of the social system theory of Vilfredo

More information

) ,

) , Vol. 2, 1 17, 2013 1986 A study about the development of the basic policy in the field of reform of China s sports system 1986 HaoWen Wu Abstract: This study focuses on the development of the basic policy

More information

How to read the marks and remarks used in this parts book. Section 1 : Explanation of Code Use In MRK Column OO : Interchangeable between the new part

How to read the marks and remarks used in this parts book. Section 1 : Explanation of Code Use In MRK Column OO : Interchangeable between the new part Reservdelskatalog MIKASA MVC-50 vibratorplatta EPOX Maskin AB Postadress Besöksadress Telefon Fax e-post Hemsida Version Box 6060 Landsvägen 1 08-754 71 60 08-754 81 00 info@epox.se www.epox.se 1,0 192

More information

ON A FEW INFLUENCES OF THE DENTAL CARIES IN THE ELEMENTARY SCHOOL PUPIL BY Teruko KASAKURA, Naonobu IWAI, Sachio TAKADA Department of Hygiene, Nippon Dental College (Director: Prof. T. Niwa) The relationship

More information

5 11 3 1....1 2. 5...4 (1)...5...6...7...17...22 (2)...70...71...72...77...82 (3)...85...86...87...92...97 (4)...101...102...103...112...117 (5)...121...122...123...125...128 1. 10 Web Web WG 5 4 5 ²

More information

スライド 1

スライド 1 県立広島病院輸血部 藤井明美 その他 造血幹移植 臓器移植 輸血関連 SSP 法のみ その他 造血幹移植 臓器移植 輸血関連 SSP 法のみ 参加部門 a b c d 参加部門 a b c d No. DNA-QC Lab. No. 使用試薬 No. DNA-QC Lab. No. 使用試薬 1 25D04 H-1,H-2 2 25D06 L-1 3 25D10 L-4 4 25D11 L-2 5

More information

Clustering in Time and Periodicity of Strong Earthquakes in Tokyo Masami OKADA Kobe Marine Observatory (Received on March 30, 1977) The clustering in time and periodicity of earthquake occurrence are investigated

More information

Web Stamps 96 KJ Stamps Web Vol 8, No 1, 2004

Web Stamps 96 KJ Stamps Web Vol 8, No 1, 2004 The Journal of the Japan Academy of Nursing Administration and Policies Vol 8, No 1, pp 43 _ 57, 2004 The Literature Review of the Japanese Nurses Job Satisfaction Research Which the Stamps-Ozaki Scale

More information

浜松医科大学紀要

浜松医科大学紀要 On the Statistical Bias Found in the Horse Racing Data (1) Akio NODA Mathematics Abstract: The purpose of the present paper is to report what type of statistical bias the author has found in the horse

More information

Abstract 1 1 2 Abstract Fig. 1 Fig. 2 Fig. 3 Abstract 1 2 3 4 5 6 7 8 10 9 Abstract 1 1 2 3 4 5 6 7 8 9 Abstract 1 2 3 4 Abstract 1 1 2 2 3 4 5 6 3 7 8 9 4 Abstract 1 2 3 4 5 6 7 8 9 10

More information

How to read the marks and remarks used in this parts book. Section 1 : Explanation of Code Use In MRK Column OO : Interchangeable between the new part

How to read the marks and remarks used in this parts book. Section 1 : Explanation of Code Use In MRK Column OO : Interchangeable between the new part Reservdelskatalog MIKASA MCD-L14 asfalt- och betongsåg EPOX Maskin AB Postadress Besöksadress Telefon Fax e-post Hemsida Version Box 6060 Landsvägen 1 08-754 71 60 08-754 81 00 info@epox.se www.epox.se

More information

The nursing practices nurses consider important in the tertiary emergency rooms Kanako Honda'', Chizuko Miyake'', Midori Yao", Mikiko Kurushima", Kumiko Toyoda4 "The University of Shiga Prefecture, "Osaka

More information

Contents Logging in 3-14 Downloading files from e-ijlp 15 Submitting files on e-ijlp Sending messages to instructors Setting up automatic

Contents Logging in 3-14 Downloading files from e-ijlp 15 Submitting files on e-ijlp Sending messages to instructors Setting up automatic e-ijlp(lms) の使い方 How to Use e-ijlp(lms) 学生用 / Guidance for Students (ver. 2.1) 2018.3.26 金沢大学総合日本語プログラム Integrated Japanese Language Program Kanazawa University Contents Logging in 3-14 Downloading files

More information

Page 1 of 6 B (The World of Mathematics) November 20, 2006 Final Exam 2006 Division: ID#: Name: 1. p, q, r (Let p, q, r are propositions. ) (10pts) (a

Page 1 of 6 B (The World of Mathematics) November 20, 2006 Final Exam 2006 Division: ID#: Name: 1. p, q, r (Let p, q, r are propositions. ) (10pts) (a Page 1 of 6 B (The World of Mathematics) November 0, 006 Final Exam 006 Division: ID#: Name: 1. p, q, r (Let p, q, r are propositions. ) (a) (Decide whether the following holds by completing the truth

More information

_念3)医療2009_夏.indd

_念3)医療2009_夏.indd Evaluation of the Social Benefits of the Regional Medical System Based on Land Price Information -A Hedonic Valuation of the Sense of Relief Provided by Health Care Facilities- Takuma Sugahara Ph.D. Abstract

More information

学位研究17号

学位研究17号 1715 3 The Student Transfer and the Articulation System in Chinese Higher Education HUANG Meiying Research in Academic Degrees, No. 17 March, 2003the article The Journal on Academic Degrees of National

More information

16_.....E...._.I.v2006

16_.....E...._.I.v2006 55 1 18 Bull. Nara Univ. Educ., Vol. 55, No.1 (Cult. & Soc.), 2006 165 2002 * 18 Collaboration Between a School Athletic Club and a Community Sports Club A Case Study of SOLESTRELLA NARA 2002 Rie TAKAMURA

More information

NINJAL Research Papers No.8

NINJAL Research Papers No.8 (NINJAL Research Papers) 8: 177 196 (2014) ISSN: 2186-134X print/2186-1358 online 177 3 3 3 1940 3 late adoption real time 3 apparent time * 1. 1 2 3 1.1 3 1 1953 * 2014 3 18 2014 5 13 109 NINJAL 2012

More information

ñ{ï 01-65

ñ{ï 01-65 191252005.2 19 *1 *2 *3 19562000 45 10 10 Abstract A review of annual change in leading rice varieties for the 45 years between 1956 and 2000 in Japan yielded 10 leading varieties of non-glutinous lowland

More information

Abstract Journal of Agricultural Science 2

Abstract Journal of Agricultural Science 2 Cambridge Journals Online Cambridge University Press 2003 1 Cambridge University Press URL: http://www.journals.cambridge.org/ Cambridge Journal Online My CJO Browse Journals Subscribed Journals Subscribed

More information

On the Wireless Beam of Short Electric Waves. (VII) (A New Electric Wave Projector.) By S. UDA, Member (Tohoku Imperial University.) Abstract. A new e

On the Wireless Beam of Short Electric Waves. (VII) (A New Electric Wave Projector.) By S. UDA, Member (Tohoku Imperial University.) Abstract. A new e On the Wireless Beam of Short Electric Waves. (VII) (A New Electric Wave Projector.) By S. UDA, Member (Tohoku Imperial University.) Abstract. A new electric wave projector is proposed in this paper. The

More information

elemmay09.pub

elemmay09.pub Elementary Activity Bank Activity Bank Activity Bank Activity Bank Activity Bank Activity Bank Activity Bank Activity Bank Activity Bank Activity Bank Activity Bank Activity Bank Number Challenge Time:

More information

MOMW_I_,II 利用ガイド.PDF

MOMW_I_,II 利用ガイド.PDF MOMW (I), II 1 The Making of the Modern World I. The Making of the Modern World... 2 II.... 3 II-1... 3 II-2 Basic Search... 4 II-3... 5 II-4 Advanced Search... 9 II-5... 13 III.... 14 III-1... 14 III-2...

More information

22-1.indb

22-1.indb 22 1 27 4 20 24 1 2015 3 27 HLA 6 7 26 HLA 8 2015 11 18 HLA-QC 12 DNA Luminex 16 DNA SSO INNO-LiPA 18 DNA SSP 20 DNA SBT 22 FlowPRA 25 LABScreen 26 WAKFlow 28 30 DNA-QC 31 33 QCWS 35 総説 HLA T 37 13 44

More information

Title < 論文 > 公立学校における在日韓国 朝鮮人教育の位置に関する社会学的考察 : 大阪と京都における 民族学級 の事例から Author(s) 金, 兌恩 Citation 京都社会学年報 : KJS = Kyoto journal of so 14: 21-41 Issue Date 2006-12-25 URL http://hdl.handle.net/2433/192679 Right

More information

44 2012 2013 3 35 48 法人化後の国立大学の収入変動 37 法人化後の国立大学の収入変動 2009 2005 2010 2012 2012 2008 2009a 2010 16 18 17 20 2 4 2012 38 44 2012 17 22 (1) (2) 2012 5 GP COE 30 WPI 1 2012 17 22 16 17 22 17 17 19 2012 2012

More information

137 Author s E-mail Address: torii@shoin.ac.jp Relationship between appearance modifying behavior and narcissistic tendency in Japanese males TORII Sakura Faculty of Human Sciences, Kobe Shoin Women s

More information